Modified myocardial performance index for evaluation of fetal heart function and perinatal outcomes in intrahepatic pregnancy cholestasis

Ömeroğlu, İbrahim; Gölbaşı, Hakan; Bayraktar, Burak; Gölbaşı, Ceren; Karaca, Suna Yıldırım; Demircan, Tülay; Ekin, Atalay

doi:10.1007/s10554-022-02789-4

Cited by 2 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…Of the studies included in this systematic review and meta-analysis, 7 were case-control 22,24,29,30,33,37,36 and 3 were cohort. 32,34,37 The studies were conducted in China, 33,32,34,37,35 Turkey, 24,36 France, 22 India, 30 and Holland. 29 Additionally, 6 of the included studies provided information about the treatment of pregnant individuals with ICP, and it was determined that UDCA was used at different doses in all of them 22,24,29,30,35,36 (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…Every study included in this systematic review scored greater than 50% on the quality checklist. Seven of the studies synthesized in this systematic review and meta-analysis were of moderate quality, 22,24,29,33,32,34,37 and three were of good quality 30,35,36 (Table 1).…”

Section: Evaluation Of Methodological Quality Of Studiesmentioning

confidence: 99%

“…The most prevalent fetal adverse outcome is intrauterine fetal death. [22][23][24] The aim of a systematic review and meta-analysis, prepared by bringing together research results appraised by quality assessment tools and conducting a critical analysis, is to obtain the best evidence about the subject. 25 Although there are comprehensive studies on the clinical symptoms, signs, and treatments of ICP in the literature, 17,[26][27][28][29] systematic reviews and meta-analyses regarding the incidence and maternal, fetal, and neonatal outcomes of ICP are limited.…”

Section: Introductionmentioning

confidence: 99%

“…In addition to maternal adverse outcomes, fetal adverse outcomes that increase morbidity and mortality rates include meconium‐stained amniotic fluid, fetal distress, respiratory distress syndrome, preterm birth, low Apgar scores, and increased need for neonatal intensive care unit (NICU) monitoring. The most prevalent fetal adverse outcome is intrauterine fetal death 22–24 …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The Incidence of Intrahepatic Cholestasis of Pregnancy and its Maternal, Fetal, and Neonatal Adverse Outcomes: A Systematic Review and Meta‐Analysis

Odabaş,

Sökmen,

Dünder

et al. 2024

J Midwife Womens Health

View full text Add to dashboard Cite

IntroductionIntrahepatic cholestasis of pregnancy (ICP) is a problem with an increasing incidence and negative maternal, fetal, and neonatal consequences. This problem is becoming increasingly important. This systematic review and meta‐analysis aimed to determine the incidence of ICP and its adverse maternal, fetal, and neonatal adverse outcomes based on primary research studies.MethodsThis systematic review and meta‐analysis used Preferred Reporting Items for Systematic Reviews and Meta‐Analyses reporting guidelines and was conducted between June and September 2023 using the following keywords: obstetric cholestasis OR intrahepatic cholestasis AND pregnancy OR pregnant OR prenatal OR antenatal OR perinatal OR maternal OR fetal OR neonatal. Quality assessment of the studies was performed using the Critical Appraisal Checklists developed by the JBI Institute. Data were synthesized using meta‐analysis methods.ResultsThe analysis included 10 studies published between 2013 and 2023. The meta‐analysis showed that the incidence of ICP was 1.7% (odds ratio [OR], 0.021; 95% CI, 0.012‐0.027), whereas maternal, fetal, and neonatal adverse outcomes included cesarean birth (OR, 2.938; 95% CI, 1.467‐5.881), preterm birth or preterm prelabor rupture of membranes (OR, 4.241; 95% CI, 1.996‐9.009), hypertensive disorders of pregnancy (OR, 3.715; 95% CI, 1.545‐8.929), maternal infection (OR, 3.301; 95% CI, 2.917‐3.737), neonatal intensive care unit admission (OR, 2.715; 95% CI, 1.458‐5.056), birth weight less than or equal to 2500 g (OR, 2.518; 95% CI, 1.296‐4.892), and small for gestational age (OR, 1.915; 95% CI, 1.424‐2.573).DiscussionThis systematic review and meta‐analysis revealed that ICP has a high incidence and several maternal, fetal, and neonatal adverse outcomes. Therefore, midwives and other health professionals must be aware of these outcomes and provide appropriate care to pregnant individuals with ICP.

show abstract